Around 3,000 lives could be saved ‘by changes to heart failure treatment'
New draft guidelines from the National Institute for Health and Care Excellence (Nice) recommend medicines are given up to a year earlier.
It has looked specifically at a type of heart failure called heart failure with a reduced ejection fraction (HFrEF), which happens when the left side of the heart fails to pump blood out to the body properly.
The condition affects around 387,000 of the 614,000 adults in England with heart failure.
Nice said medics are already changing practice to ensure that the four pillars of treatment – angiotensin-converting enzyme inhibitor (ACEI), a beta-blocker (BB), a mineralocorticoid receptor antagonist (MRA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor – can be used earlier without the need to optimise the dose of any one medicine before introducing another.
Nice is recommending widespread earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozin – giving them at the start of treatment rather than waiting up to a year for dosage of other drugs to be optimised.
Generally, Nice said the drugs can also be started by GPs with advice from a heart failure specialist, rather than having to refer people to hospitals.
Eric Power, deputy director in Nice's centre for guidelines, said: 'Heart failure is common, with currently around 614,000 adults in England living with a diagnosis.
'Although there's no cure, it is treatable, and the growing number of people living with heart failure is testament to the improvements in care introduced over recent years.
'For this update we've been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments.
'This should have a big impact on the lives of people living with heart failure as well as freeing up space in hospitals by reducing their risk of having to go to hospital for unplanned emergency treatment.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Thousands of NHS patients ‘to be denied breakthrough Alzheimer's drugs'
Breakthrough drugs that slow the progression of Alzheimer's disease will reportedly be refused for use on the NHS this week in a blow to thousands of patients. The two drugs, Lecanemab and donanemab, slow down the decline in Alzheimer's patients' ability to carry out daily activities. The drugs' success in halting the progression of Alzheimer's was heralded as a 'new era' by campaigners and researchers. However, the National Institute for Health and Care Excellence (Nice) is expected to refuse to recommend them on the NHS, according to The Sunday Times. The regulator has already issued two decisions, one in October last year and another in March, saying they would not recommend the drugs for use on the NHS. A final decision will be published on Thursday. Both drugs already have UK drug licences, making them available privately. It is estimated that around 70,000 adults in England would have been eligible for treatment if the drugs had been approved. The regulator will reportedly turn down both drugs on the grounds of cost-effectiveness, with one insider telling The Sunday Times: 'It is the end of the road for these drugs on the NHS'. Lecanemab removes build-ups of the protein beta-amyloid from the brain. Trials showed that lecanemab can slow the progression of Alzheimer's by 27 per cent over 18 months if given to someone early on in the course of their decline. Donanemab, marketed as Kisunla in the UK, teaches the body's immune cells to recognise and remove the amyloid protein, which builds up in the brains of people with Alzheimer's disease. The protein build-ups are thought to be toxic to brain cells, leading to the symptoms of Alzheimer's, the Alzheimer's society has said. Lecanemab can, however, cause swelling and bleeding in the brain. In trials for Donanemab, a third of recipients experienced abnormalities in their brain scans caused by brain swelling and bleeding, NICE said. The drugs reportedly cost around £20,000 to £25,000, with the NHS being offered a lower price. Privately, the treatment costs between £60,000-80,000 per year, according to Alzheimer's Research UK. In a previous review by NICE in October 2024, director of medicines evaluation Helen Knight said: 'Donanemab could slow down cognitive decline by 4-7 months, but this is just not enough benefit to justify the additional cost to the NHS. The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources'. While the regulator said the decision would be disappointing for some, 'there are other treatments being developed'. Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said the decision to turn down the drugs would be 'deeply disappointing'. She added: 'These treatments are not perfect, and we recognise the challenges they pose around cost, delivery and safety. But scientific progress is incremental, and these drugs represent a vital foundation to build on.' The regulator NICE is due to publish the final draft guidance about the two drugs on Thursday. This leaves space for the decision to be challenged and sent to a review panel before the final guidance is published.
ITV News
2 days ago
- ITV News
World-first 'Trojan horse' drug to be given to blood cancer patients in England
Blood cancer patients in England will be among the first in the world to have access to a new 'Trojan horse' treatment, health officials have announced. Studies suggest the targeted therapy can stop myeloma from progressing by nearly three times as long as existing treatments. It is estimated that around 1,500 patients a year with multiple myeloma – an incurable cancer of the bone marrow – will benefit from the treatment. It comes after the National Institute for Health and Care Excellence (Nice) approved belantamab mafodotin, also known as Blenrep and made by GlaxoSmithKline, for NHS use. NHS England said that it is the first health system in the world to roll out the treatment. Officials said that the drug can now be offered to patients whose cancer has progressed or has not responded to another first-line treatment. The treatment, which is given as an infusion every three weeks along with other cancer drugs, is a type of antibody drug which targets and attaches to cancer cells. It has been dubbed a 'Trojan horse' treatment because it works by being taken into a cancer cell, before releasing a high concentration of a lethal molecule to destroy the cell from inside. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' Professor Peter Johnson, NHS England's national clinical director for cancer, said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family. 'This treatment could be life-changing for many patients and their families, and that's why it is so important that the NHS continues to secure quick access to the latest, innovative treatments like this, at affordable prices to the taxpayer.' Helen Knight, director of medicines evaluation at Nice, said: 'We're delighted that people in the UK will become among the first in the world to access belantamab mafodotin for this indication. 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' Trials have suggested that the treatment, in combination with bortezomib and dexamethasone, delayed progression of the disease by an average of three years, compared to just over a year for patients taking commonly used drug daratumumab along with the other treatments. Patient Paul Silvester, 60, from Sheffield, was diagnosed with myeloma in July 2023 and received treatment at the Royal Hallamshire Hospital. The first treatment he was given failed to stop his cancer from progressing so he was given belantamab mafodotin through an early access programme. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. 'It gives me quite a lot of confidence in the drugs and it makes me more optimistic about the future.'I've been feeling well and I'm still quite active – that's what's important in terms of your quality of life. 'One of my daughters is graduating from university in October and it's a goal for me to be there.' Shelagh McKinlay, director of research and advocacy at blood cancer charity Myeloma UK, said: 'It's fantastic to see the UK at the forefront of myeloma treatment. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma.' Health Minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation.'By harnessing cutting-edge 'trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
The Independent
2 days ago
- The Independent
NHS England to roll out pioneering cancer treatment in world first
NHS England will be the first health system worldwide to roll out the pioneering "Trojan horse" treatment, belantamab mafodotin (Blenrep), for blood cancer patients. The targeted therapy has shown promising results in halting the progression of myeloma for nearly three times as long as current treatments, benefitting approximately 1,500 patients annually. Blenrep, manufactured by GlaxoSmithKline, has been approved by the National Institute for Health and Care Excellence (Nice) for use within the NHS. It will be available to patients whose cancer has advanced or has not responded to initial treatments. Trials suggest that the treatment, in combination with other drugs, delayed disease progression by an average of three years, compared to just over a year for patients taking commonly used drugs.
